HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety.

AbstractPURPOSE:
Pregnancies in women with essential thrombocythemia (ET) are at a higher risk for obstetrical complications. Acetylsalicylic acid (ASA) and low-molecular weight heparin (LMWH) are common options to prevent miscarriages and maternal complications, whereas interferon alpha (IFN) seems to be the cytoreductive therapy of choice. This retrospective study analyzes the largest number of IFN pregnancies to date in terms of outcome and safety.
METHODS:
Data of 34 high-risk pregnancies in 23 women presenting at the University hospitals of Minden and Jena from 01-Jun-2007 to 01-Jun-2020 were collected. Reasons defining high-risk ET pregnancy in all 23 patients were: Thrombosis (n = 9) or severe hemorrhage (n = 2) in history, platelet count ≥ 1500 × 103/µl (n = 8) or severe microcirculatory disturbances not completely responding to ASA (n = 4).
RESULTS:
Without the use of IFN, live birth rate was 60% (6/10), however, after the use of IFN live birth rate increased to 73.5% (25/34 pregnancies). Nine pregnancies ended in miscarriages (9/34; 26.5%); all of them spontaneous abortions. Live birth rate significantly improved with ASA (90% versus 50%, p = 0.0168), however, if ASA and LMWH was added (n = 14), live birth rate was 100%. IFN compound (PEGylated versus standard IFN) and JAK2-driver mutation had no impact on pregnancy outcome. One major maternal complication occurred as a major peripartal bleeding after abortion curettage.
CONCLUSION:
IFN was associated with an encouraging live birth rate of 73.5% with no fatal maternal events and manageable side effects.
AuthorsLukas Schrickel, Florian H Heidel, Parvis Sadjadian, Tatjana Becker, Vera Kolatzki, Andreas Hochhaus, Martin Griesshammer, Kai Wille, German Study Group MPN, GSG-MPN
JournalJournal of cancer research and clinical oncology (J Cancer Res Clin Oncol) Vol. 147 Issue 5 Pg. 1481-1491 (May 2021) ISSN: 1432-1335 [Electronic] Germany
PMID33140210 (Publication Type: Journal Article)
Chemical References
  • Heparin, Low-Molecular-Weight
  • Interferon-alpha
  • Janus Kinase 2
  • Aspirin
Topics
  • Abortion, Spontaneous (metabolism, prevention & control)
  • Adult
  • Aspirin (therapeutic use)
  • Female
  • Heparin, Low-Molecular-Weight (therapeutic use)
  • Humans
  • Interferon-alpha (therapeutic use)
  • Janus Kinase 2 (metabolism)
  • Platelet Count (methods)
  • Pregnancy
  • Pregnancy Outcome
  • Pregnancy, High-Risk (drug effects, metabolism)
  • Retrospective Studies
  • Thrombocythemia, Essential (drug therapy, metabolism)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: